Biointaxis, the new spin-off company of the IGTP, was recently constituted. The company stems from research led by Dr Antoni Matilla-Dueñas together with Dr Ivelisse Sánchez of the Neurogenetics Group of the IGTP and has been created to increase translational research leading to treatments and new genomic technologies for rare neurological diseases with genetic causes. The first project the company is undertaking is the development of a gene therapy for Friedreich's Ataxia.
Dr Daniel Fuster of the Addiction Unit of the Internal Medicine Service at the Germans Trias i Pujol University Hospital and Research Institute (IGTP) and the Universitat Autònoma de Barcelona has co-authored a landmark review article on alcohol use in patients with chronic liver disease with Dr Jeffrey H Samet of Boston Medical Center and University School of Medicine. The article has been published in the New England Journal of Medicine.
PI Genomic Instability and Cancer Laboratory IRB Oncology Programme